<div style="margin: 12px 0px; font-family: arial; color: #333333; background: #ffffff; border: solid 4px #e5e5e5; width: 100%; clear: left;"><div class="CM_CTB_Content_Wrap" style="margin: 0px; padding: 0px;background-color: #ffffff;"><div style="border-bottom: solid 1px #dcdcdc; white-space: nowrap; margin-bottom: 8px; background-color: #eeeeee ;background-image: url(http://clipmarks.com/images/source-bg.gif); background-repeat: repeat-x; height: 24px; line-height: 24px; vertical-align: middle; padding-bottom: 4px; color: #666666; font-size: 10px;" ><a href="http://clipmarks.com/clip-to-blog/" title="see clips that are hot right now"><img src="http://content.clipmarks.com/blog_embed/03722ed4-481c-4f35-ab43-2852bc3bb0c5/6B482C74-441C-4009-82E9-ABB89F7C1FFE/" alt="" width="19" height="19" border="0" style="vertical-align: middle; margin: 0px 4px; display: inline; border: none; float:none;" /></a>clipped from <a title="http://www.bizjournals.com/washington/stories/2007/11/19/daily6.html?b=1195448400%5e1553029" href="http://www.bizjournals.com/washington/stories/2007/11/19/daily6.html?b=1195448400%5e1553029" style="font-size: 11px;">www.bizjournals.com</a></div><blockquote style="text-align: left; padding: 0px 8px; margin: 4px 0px 8px 0px; background: transparent; border: none;" cite="http://www.bizjournals.com/washington/stories/2007/11/19/daily6.html?b=1195448400%5e1553029"><A href="http://www.bizjournals.com/washington/gen/Emergent_BioSolutions_Inc_8D0CBA655B474550AE236F4E368FE134.html"><STRONG>Emergent BioSolutions Inc.</STRONG></A> says the Department of Health and Human Services has reaffirmed its commitment to purchasing the company's anthrax vaccine, a contract that provides a steady stream of revenue to support its growth for the next two years.</blockquote><div style="height: 2px; font-size: 2px; background: #dcdcdc; border-bottom: solid 1px #f5f5f5; margin: 2px 4px;"></div><blockquote style="text-align: left; padding: 0px 8px; margin: 4px 0px 8px 0px; background: transparent; border: none;" cite="http://www.bizjournals.com/washington/stories/2007/11/19/daily6.html?b=1195448400%5e1553029"> The government agreed in September to buy nearly 19 million doses of Emergent's BioThrax vaccine through 2010 for $400 million.</blockquote><div style="height: 2px; font-size: 2px; background: #dcdcdc; border-bottom: solid 1px #f5f5f5; margin: 2px 4px;"></div><blockquote style="text-align: left; padding: 0px 8px; margin: 4px 0px 8px 0px; background: transparent; border: none;" cite="http://www.bizjournals.com/washington/stories/2007/11/19/daily6.html?b=1195448400%5e1553029"> Emergent will get an additional $34 million if it wins regulatory approval to increase the drug's shelf life from three years to four. The company is waiting for a decision on its application to the Food and Drug Administration to extend the shelf life.</blockquote><div style="height: 2px; font-size: 2px; background: #dcdcdc; border-bottom: solid 1px #f5f5f5; margin: 2px 4px;"></div><blockquote style="text-align: left; padding: 0px 8px; margin: 4px 0px 8px 0px; background: transparent; border: none;" cite="http://www.bizjournals.com/washington/stories/2007/11/19/daily6.html?b=1195448400%5e1553029"> Emergent BioSolutions </blockquote><div style="height: 2px; font-size: 2px; background: #dcdcdc; border-bottom: solid 1px #f5f5f5; margin: 2px 4px;"></div><blockquote style="text-align: left; padding: 0px 8px; margin: 4px 0px 8px 0px; background: transparent; border: none;" cite="http://www.bizjournals.com/washington/stories/2007/11/19/daily6.html?b=1195448400%5e1553029"><P> The drug is approved for pre-exposure vaccination. Emergent is also testing it as a post-exposure vaccine, which, if successful, will earn an additional $11.5 million from HHS. One round of post-exposure clinical trials has already triggered an $8.8 million milestone payment. </P></blockquote><div style="height: 2px; font-size: 2px; background: #dcdcdc; border-bottom: solid 1px #f5f5f5; margin: 2px 4px;"></div><blockquote style="text-align: left; padding: 0px 8px; margin: 4px 0px 8px 0px; background: transparent; border: none;" cite="http://www.bizjournals.com/washington/stories/2007/11/19/daily6.html?b=1195448400%5e1553029">working on a typhoid vaccine</blockquote><div style="height: 2px; font-size: 2px; background: #dcdcdc; border-bottom: solid 1px #f5f5f5; margin: 2px 4px;"></div><blockquote style="text-align: left; padding: 0px 8px; margin: 4px 0px 8px 0px; background: transparent; border: none;" cite="http://www.bizjournals.com/washington/stories/2007/11/19/daily6.html?b=1195448400%5e1553029">completed Phase II clinical trials.</blockquote></div><div style="margin: 0px 6px 6px 4px;"><table style="font-size: 11px;border-spacing: 0px;padding: 0px;" cellpadding="0" cellspacing="0" width="100%"><tr><td style="background:transparent;border-width:0px;padding:0px;">&nbsp;</td><td align="right" style="background:transparent;border-width:0px;padding:0px;width:107px" width="107"><a href="http://clipmarks.com/share/6B482C74-441C-4009-82E9-ABB89F7C1FFE/blog/" title="blog or email this clip"><img src="http://content9.clipmarks.com/images/c2b-foot.png" border="0" alt="blog it" width="107" height="17" style="border-width:0px;padding:0px;margin:0px;" /></a></td></tr></table></div></div>

New from the makers of Clipmarks:  Amplify.com - Don't just share the news...Amplify it!